![itziar_erkizia_edited.jpg](/sites/default/files/styles/1_1_small/public/imports/dest/drupal7_imatges/itziar_erkizia_edited.jpg?h=1f3fdc12&itok=zF2KlgRi)
Itziar Erkizia Jauregi
Técnico/a sénior de laboratorio
Grupo de investigación
Preclinical development of humanized monoclonal antibodies against CD169 as a broad antiviral therapeutic strategy.
Impact of obefazimod on viral persistence, inflammation, and immune activation in people with HIV on suppressive antiretroviral therapy.
Author Correction to: SARS-CoV-2 interaction with Siglec-1 mediates trans-infection by dendritic cells.
Maturation of blood-derived dendritic cells enhances human immunodeficiency virus type 1 capture and transmission.
A non-infectious cell-based phenotypic assay for the assessment of HIV-1 susceptibility to protease inhibitors.